Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic - 29/04/23
, Tara Elizabeth Scott a, Wojciech Waldman b, Jacek Sein Anand b, Marek Wiergowski c, Ivan Kocić a
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Background |
The COVID-19 pandemic has caused significant changes to the global health care system
Aims |
It is unknown whether the COVID-19 pandemic influenced the occurrence of adverse drug reactions (ADR) of antidepressive agents, benzodiazepines, and antipsychotics plus mood stabilizers (AaMS). The study was designed in order to compare the incidence of ADR during the COVID-19 pandemic with the period preceding the pandemic in Poland and Australia, different in terms of their COVID-19 prevention strategy.
Method |
We analysed ADR from the three surveyed pharmacological groups of drugs observed in Poland and Australia in the period prior to, and during the COVID-19 pandemic
Results |
In Poland, a noticeable increase in the reported ADR of the assessed drug groups was observed during the COVID-19 pandemic. The highest was for antidepressive agents, but the reporting of ADR for benzodiazepines and AaMS drugs also increased significantly. In the case of ADR in Australian patients, the increase in the number of reported ADR for antidepressive agents was modest compared to that seen in Poland, but still noticeable, and there was a significant increase in ADR for benzodiazepines
Conclusions |
This study showed that the COVID-19 pandemic has had an impact on the incidence of ADR reported among both Polish and Australian patients but the modality of this was different.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Highlights |
• | During the pandemic, increases in the reporting of adverse reactions of psychotropic drugs were seen in Poland. |
• | In Poland was an increase in the reporting of severe adverse drug reactions compared to the period before the COVID-19 pandemic. |
• | In Australia, during the pandemic a substantial upsurge in the reporting of adverse drug reaction was found in the case of benzodiazepines. |
• | The study highlighted the differences in adverse drug reaction reporting systems between Poland and Australia. |
Keywords : Psychotropic drugs, Poland, Australia, COVID-19, Adverse drug reactions
Mappa
Vol 162
Articolo 114681- Giugno 2023 Ritorno al numero
Articolo precedente
- Baicalin ameliorates multidrug-resistant Pseudomonas aeruginosa induced pulmonary inflammation in rat via arginine biosynthesis
- Lei Li, Herong Cui, Yue Zhang, Wei Xie, Ying Lin, Yufei Guo, Tingxuan Huang, Bei Xue, Wenbo Guo, Zhenfeng Huang, Tian Man, Huiyong Yu, Zhiguang Zhai, Miao Cheng, Mingzhe Wang, Haimin Lei, Chengxiang Wang
- Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases
- Nikki S. IJzerman, Wills F. Filipe, Peter de Bruijn, Florian E. Buisman, Leni van Doorn, Pascal G. Doornebosch, Jessica J. Holster, Cecile Grootscholten, Dirk J. Grünhagen, Christian P.E. van Bommel, Marjolein Y.V. Homs, Niels F.M. Kok, Cornelis Verhoef, Bas Groot Koerkamp, Koert F.D. Kuhlmann, Ron H.J. Mathijssen, Stijn L.W. Koolen
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.